Skye Bioscience (SKYE) Depreciation & Amortization (CF) (2013 - 2026)
Skye Bioscience (SKYE) posted quarterly Depreciation & Amortization (CF) of $172886.0 for Q1 2026, down 2.53% year-over-year from $177379.0 in Q1 2025, and down 3.96% quarter-over-quarter from $180009.0 in Q4 2025.
Skye Bioscience (SKYE) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Depreciation & Amortization (CF) for 14 consecutive years, with $172886.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 2.53% year-over-year to $172886.0; the TTM figure through Mar 2026 stood at $718859.0 (up 60.3% YoY), while the FY2025 annual figure was $723352.0, up 142.22% from the prior year.
- Depreciation & Amortization (CF) fell to $172886.0 in Q1 2026 per SKYE's latest filing, from $180009.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $187066.0 in Q2 2025 and bottomed at -$45971.0 in Q4 2023.
- Historically, Depreciation & Amortization (CF) has averaged $79987.4 across 5 years, with a median of $33174.0 in 2023.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 2776.12% — and 2023, when it sank 245.79%.
- Skye Bioscience's Depreciation & Amortization (CF) stood at $31532.0 in 2022, then tumbled by 245.79% to -$45971.0 in 2023, then surged by 481.31% to $175293.0 in 2024, then advanced by 2.69% to $180009.0 in 2025, then fell by 3.96% to $172886.0 in 2026.
- Business Quant data shows SKYE's Depreciation & Amortization (CF) at $172886.0 in Q1 2026, $180009.0 in Q4 2025, and $178898.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - | 157,598.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 172,886.00 |
| Mar 31, 2026 | 172,886.00 |
| Dec 31, 2025 | 180,009.00 |
| Dec 31, 2025 | 180,009.00 |
| Sep 30, 2025 | 178,898.00 |
| Sep 30, 2025 | 178,898.00 |
| Jun 30, 2025 | 187,066.00 |
| Jun 30, 2025 | 187,066.00 |
| Mar 31, 2025 | 177,379.00 |
| Mar 31, 2025 | 177,379.00 |
| Dec 31, 2024 | 175,293.00 |
| Dec 31, 2024 | 175,293.00 |
| Sep 30, 2024 | 65,997.00 |
| Sep 30, 2024 | 65,997.00 |
| Jun 30, 2024 | 29,790.00 |
| Jun 30, 2024 | 29,790.00 |
| Mar 31, 2024 | 27,560.00 |
| Mar 31, 2024 | 27,560.00 |
| Dec 31, 2023 | -45,971.00 |
| Dec 31, 2023 | -45,971.00 |